Serum galactomannan antigen test for the diagnosis of chronic pulmonary aspergillosis
Introduction
The chronic forms of pulmonary aspergillosis are simple aspergilloma, chronic cavitary pulmonary aspergillosis (CCPA), and chronic necrotizing pulmonary aspergillosis (CNPA).1 Although certain authors distinguish chronic fibrosing pulmonary aspergillosis (CFPA) from CCPA,2 many investigators have described CCPA, CFPA, and CNPA as chronic pulmonary aspergillosis (CPA) in the recent literature.3, 4, 5
The diagnosis of CPA is difficult and is generally based on a constellation of clinical signs and symptoms, radiologic manifestations, and microbiological evidence, including the positive isolation of Aspergillus species from respiratory tract samples.6, 7, 8, 9 However, in patients with CPA, the role of conventional culture is limited by low sensitivity and relatively delayed results.10 Therefore, a serum Aspergillus precipitin antibody test has been widely used for the serologic diagnosis of CPA.6, 7, 8, 10
Galactomannan (GM) is a component of the Aspergillus species cell wall and is released into the surrounding environment during fungal growth or tissue invasion.11 A serum GM antigen test has been widely used to diagnose invasive pulmonary aspergillosis.12 However, there are limited data on the use of the serum GM antigen test in patients with CPA.4, 10, 13, 14 Therefore, we investigated the diagnostic performance of the serum GM antigen test to evaluate the utility of the test for the serologic diagnosis of CPA.
Section snippets
Patients and methods
Data were collected from all consecutive patients with a clinical suspicion of CPA who underwent a serum GM antigen test at the Samsung Medical Center (a 1961-bed, university-affiliated, tertiary referral hospital in Seoul, South Korea) between January 2010 and December 2012 and were retrospectively analyzed. A portion of the clinical data from these patients was included in an article published in 2013.9 Immunocompromised patients, such as those with neutropenia, hematological malignancy, or
Results
During the study period, a total of 334 patients who were suspected to have CPA were eligible for this study. The clinical characteristics of the patients are presented in Table 1. Most patients had underlying lung disease, such as previous tuberculosis (n = 254, 76%), bronchiectasis (n = 181, 54%), or nontuberculous mycobacterial lung disease (n = 120, 36%). All patients presented with at least one of the following chest CT findings: cavity (n = 301, 90%), consolidation (n = 214, 64%),
Discussion
In the present study, we evaluated the utility of the serum GM antigen test for the diagnosis of CPA using a relatively large number of patients who were suspected to have CPA. However, the diagnostic performance of the serum GM antigen test was not acceptable for use in clinical practice due to low accuracy and discriminatory power.
The serum GM antigen test was originally studied and approved for use in the diagnosis of invasive aspergillosis.12 Recently, this test was evaluated as a method to
Conflict of interest statement
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Acknowledgments
This work was supported by a Samsung Biomedical Research Institute grant (SBRI C-B1-101).
References (15)
- et al.
Treatment of chronic pulmonary aspergillosis by voriconazole in nonimmunocompromised patients
Chest
(2007) - et al.
Clinical characteristics and prognosis of chronic pulmonary aspergillosis
Respir Med
(2012) - et al.
Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases
Int J Infect Dis
(2010) - et al.
Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis
Lancet Infect Dis
(2004) - et al.
The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosis
Respir Med
(2013) - et al.
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America
Clin Infect Dis
(2008) - et al.
Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma
Eur Respir J
(2011)
Cited by (0)
- c
Beomsu Shin and Won-Jung Koh contributed equally to this work.